Api list_1.10.2012 final 1.10.2012 print

Active Pharmaceutical Ingredients*
Commercial Scale
Antitubercular
Macrolides
Antimalarial
Sedative, Hypnotic
Antihypertensive
Antifungal
Antiepileptic
Antiosteoporotic
Antihistaminic
Antidepressant
Meclizine dihydrochloride+
Under Development
# US DMF + CTD filing under process * WHO APIMF CEP / COS *The Technical and Physical manufacturing capabilities exist with us for the above APIs and their intermediates. However these products will be offered onlyto the markets where any product or process patents are not infringing. During the validity of a patent the research quantities for developing productsfor regulatory submissions will only be offered to countries where such exemption exists (Hatch Waxman Act / Bolar exemption). While Calyx offers to work with the clients on Patent Status Verification, the final responsibility vests with the buyer. Recipients are requested to make their evaluation and determination as to the patent status prior to their use of the information or materials in their respective jurisdiction.
Products under patent offered only for exempted research, clinical and development purposes. Only non-infringing products and processes are offered, subject to patent status verification by client. Calyx Chemicals and Pharmaceuticals Limited
Reg. Office: Unit No.110, Marwah’s Complex, Krishanlal Marwah Marg, Off. Saki Vihar Road, Andheri (East), Mumbai – 400072, Maharashtra, India.
Tel: +91-22-28571191 Fax: +91-22-66466416 USA Contact: 11728 E. Imperial Highway, Norwalk, CA 90650, Tel - 213-291-7773 Email: sales@calyxindia.com, crams@calyxindia.com, sales@calyxusa.com, crams@calyxusa.com, www.calyxindia.com "Calyx Chemicals and Pharmaceuticals Limited (the “Company”) is proposing to make, subject to receipt of requisite approvals, market conditions and other considerations, an Initial
Public Offering of its equity shares (the “IPO") and has filed the Draft Red Herring Prospectus (the “DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is
available on the website of SEBI at www.sebi.gov.in, the website of the BRLMs, i.e. PL Capital Markets Private Limited at www.plindia.com and YES Bank Limited at www.yesbank.in
and is also available on the website of the Company at www.calyx-pharma.com. Potential investors should note that investment in equity shares involves a degree of risk. For details,
please refer to the DRHP, including the section titled “Risk Factors” of the DRHP. This publicity material does not constitute an offer of securities in any jurisdiction, including the United
States of America (“USA”). Securities may not be offered or sold in the USA without registration under the U.S. Securities Act of 1933 as amended, or an exemption therefrom. The
Company has not and does not intend to offer any securities to the public in the USA.

Source: http://calyx-pharma.com/api.pdf